World Journal of
Pharmaceutical and Life Sciences

A PHARMACOECONOMIC ANALYSIS TO STUDY THE RELATIVE COST EFFECTIVENESS OF BRIMONIDINE 0.2% VERSUS DORZOLAMIDE 2.0% EYE DROPS IN PATIENTS OF OPEN ANGLE GLAUCOMA/OCULAR HYPERTENSION

Dr. Neetu Sharma*, Dr. Anita Gupta and Dr. Gursatinder Singh

ABSTRACT

A Comparison of cost effectiveness of brimonidine (0.2%) versus dorzolamide (2.0%) in primary open angle glaucoma or ocular hypertension. In this open, randomized, cross over comparative study, 30 subjects of primary open angle glaucoma with IOP > 22 mmHg were taken. The patients fulfilling the inclusion criteria and after verifying the exclusion criteria were included in the study after a written informed consent. These subjects were randomized to receive brimonidine (0.2%) TDS or dorzolamide (2.0%) TDS for 4 weeks. After a wash out period of 4 weeks the subjects were crossed over to other therapy. The IOP was measured after dosing at each baseline and at the end of each treatment period. Monotherapy with brimonidine (0.2%) TDS and dorzolamide (2.0%) TDS given for 4 weeks had caused overall reduction in IOP of 5.833+2.102mmHg (23.48%) and 5.433+ 2.582mmHg (22.42%) respectively at peak levels. The difference is statistically insignificant (p>0.05). Overall monotherapy with brimonidine with Rs. appears to be more cost effective compared to dorzolamide with Rs. 12.90 - 29.50 /mm Hg and Rs. 35.60 - 100.20 /mm Hg IOP lowering efficacy respectively.

[Full Text Article]   [Download Certificate]